Member Info for lofas

…can go up or down.
Good the distinguished analysis did not consider sideways. I’m sure there is a probability for that as well.
Come on England!

Don’t think it’s an in-depth analysis. They are puzzled as to why they have not recommended SC in their periodical publication and trying to find a reasonable answer to that. Coming back to probabilities…I am confident that Vulpes didn’t use this as their basis for inverting in SC. Beside, they are so many moving partials to base one’s assessment on that. Well if you can suggest a model, then your are probably a better mathematician than me. No disrespect to any analysis including Motley, the bottom line is less than satisfactory.

He thinks it’s pure speculative, why, because “If good news comes through, in the form of successful trial results, more licensing deals or a takeover bid by a bigger pharma rival, I think Scancell shares could rocket in 2023. But equally, if there is disappointing news from a trial, the Scancell share price could crash.”
Well, what he is saying is that price can go up or down. What a breakthrough conclusion.

Partial response is expected soon to be transformed to major response. Melting is seems to go full steam ahead. Lady X is expecting to have another checkpoint in 12 weeks time. In case there is a linear relationship time/shrinkage, than the inoperable disease may vanish from the radiography screen. If that is not a miracle, what is.

No preference…..As long as they deposit £8 (minimum) for each of the common stock…:-)

Bion… ?after all the years. Don’t think so. Their platform is tailor made and may want to keep it this way. Beside, maintaining a steady stream of income may not be as urgent as it is for other big Pharma , Merck and the like of them. Hence pending outcome of current trial, which all indicators pointing to outstanding outcome we may witness something extraordinary.

Rat, angina now ? Give us clear and meaningful update.

Trying to gain 1-2p is fairly risky. Dump and you may find yourself sitting on a modest profit and likely pay more to re-enter.

£8 =~ Juno deal. On paper SC has loads to ofer.

Sp may go up/down/sideways and any other direction. However read this once, twice 3times and concluded that a wet wipe is better they trying to figure what to to with this pile.

30p is annoyingly modest. If it safe effective and comparably simple to administrate and response deviation in the cohort is less than significant, than that will ignite the debate, imagination and market value.
Is it safe ? We know the dose went up over the trial life cycle.
If it effective ? We know response was over 30% reduction. Albeit exhibit in one patient…is there is another drug in the billion dollar market that is capable to deliver that?
Simple to admin ? I think we can say yes to that.
Next update will give us the clues as to how extraordinary this platform is.

Thanks.

Who is WW and what is the issue can someone help?

Agree. Below expected result would have travelled very fast. All points to result that SC would have liked to control in terms of what and how it will get communicated.

Nop. Depending on the opportunity , Will continue to add. You must be insane to give then away for pennies.

Seeing the SP sliding may be a challenge and potentially can derail and entice one to press that he sell button. This can intensify if you add the RSI BS to the mix. If you find yourself in such position and you can’t wait for the science to do the talking at least read Chillpill useful comments on this and other thread before committing yourself.

We had a great AGM + Very positive RNS and very emotional feedback fro X. SP rise from 12 p to 25p and since drop 2.5p to 22p/23p. It looks that mood has changed as if we have nothing else in the pipeline and all recent posts are centred around Hasibas 2cents input. The gloomy mood set in for no good reason….as if LD concluded that the results are less than promising.

We had 3 updates, one formal RNS and 2 informal post from X. All pointing to success. What we don’t have is the degree. I think we also had an update of toxicity and all so far is positive. Surely we don’t expect response to be as it was a month ago? Progress seems inevitable…however it looks some folks don’t get it.

BionTech Are definitely a strong candidate and their interest was already confirmed by LD. I of cause the data and outcome can ignite the debate. Great response and Consistent result will push the price into completely different bracket. This will get the attention of major pharma as they will need a breakthrough product to safe guard their future stream of income. If it will come to that, then exchange will be in excess of £10B and we had some previous example … JUNO…to demo what price can go to when product is effective exclusive and simple to admin.

And rising…